Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase EARLY_PHASE1 3Phase 2 2Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Gastrointestinal 2Dermatologic 2Breast 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Breast Neoplasms 2Paget's Disease, Mammary 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 349Paclitaxel 310Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 215Letrozole 185Fulvestrant 178Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 114pembrolizumab 113Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 66Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Docosahexaenoic Acids × Breast × Clear all
NCT03831178 2025-06-26

DHA-WIN

AHS Cancer Control Alberta

Phase 2 Active not recruiting
76 enrolled
Breast

Breast Neoplasms

NCT01849250 2021-12-28

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

National Cancer Institute (NCI)

Phase 2 Completed
65 enrolled 11 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Paget's Disease, Mammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡